Table 1. Clinical characteristics of the study participants.
| P-value |
|||||
|---|---|---|---|---|---|
| AERD (n=139) | ATA (n=171) | NC (n=160) | AERD vs ATA | AERD vs NC | |
| Age, years | 46.45±13.88/139 | 39.78±14.08/171 | 30.48±10.31/156 | <0.001 | <0.001 |
| Sex (male/total) | 51/139 (36.7%) | 79/171 (46.2%) | 72/160 (45.0%) | 0.092 | 0.145 |
| Atopy | 60/137 (43.8%) | 112/171 (65.5%) | 15/134 (11.2%) | <0.001 | <0.001 |
| Nasal polyp | 59/121 (48.8%) | 7/169 (4.1%) | NA | <0.001 | NA |
| FEV1 (% predicted) | 79.34±21.67/138 | 88.87±20.17/167 | NA | <0.001 | NA |
| Fall_FEV1 (% predicted) | 24.50±11.67/100 | 7.27±3.79/68 | NA | <0.001 | NA |
| Log methacholine PC20 (mg ml−1) | −0.02±1.48/105 | 1.12±1.67/151 | NA | <0.001 | NA |
| Log TEC (cells μl−1) | 5.72±0.96/109 | 5.53±1.05/171 | NA | 0.129 | NA |
| Log ECP (μg l−1) | 2.58±0.99/63 | 2.70±1.00/58 | NA | 0.485 | NA |
| Log Total IgE (IU ml−1) | 5.00±1.33/131 | 5.14±1.52/164 | 3.55±1.35/41 | 0.414 | <0.001 |
| SEA–IgE (positive/total) | 12/80 (15.0%) | 11/66 (16.7%) | 5/58 (8.6%) | 0.783 | 0.260 |
| SEB–IgE (positive/total) | 19/80 (23.8%) | 12/66 (18.2%) | 3/52 (5.8%) | 0.413 | 0.007 |
| TSST-1–IgE (positive/total) | 15/80 (18.8%) | 18/66 (27.3%) | 2/61 (3.3%) | 0.220 | 0.005 |
Abbreviations: AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; ECP, eosinophil cationic protein; FEV1, forced expiratory volume in 1 s; IgE, immunoglobulin E; methacholine PC20, the provocative concentration of methacholine required to cause a 20% fall in FEV1; NA, not applicable; NC, normal controls; SEA, staphylococcal enterotoxin A; SEB, staphylococcal enterotoxin B; TEC, total eosinophil count; TSST-1, toxic shock syndrome toxin 1.
Values represent the means±s.d.